Prevalence and Landscape of Pathogenic or Likely Pathogenic Germline Variants and Their Association With Somatic Phenotype in Unselected Chinese Patients With Gynecologic Cancers
Hao Wen(Second Affiliated Hospital of Nanjing Medical University), Xiaohua Wu(Fudan University Shanghai Cancer Center), Huawen Li(Jinan University), Qin Xu(Anhui Medical University), Xipeng Wang(Shanghai Jiao Tong University), Xiujie Sheng(Third Affiliated Hospital of Guangzhou Medical University)
Cited by 10
Related Papers
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|214
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆
|Annals of Oncology|2021|212
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer
|JAMA Oncology|2023|165
Ovarian Cancer-Intrinsic Fatty Acid Synthase Prevents Anti-tumor Immunity by Disrupting Tumor-Infiltrating Dendritic Cells
|Frontiers in Immunology|2018|156
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials
|Cancer Treatment Reviews|2022|135